| First Author | Ke R | Year | 2024 |
| Journal | Oncogene | Volume | 43 |
| Issue | 30 | Pages | 2307-2324 |
| PubMed ID | 38858590 | Mgi Jnum | J:352494 |
| Mgi Id | MGI:7706290 | Doi | 10.1038/s41388-024-03055-8 |
| Citation | Ke R, et al. (2024) MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFbeta pathway. Oncogene 43(30):2307-2324 |
| abstractText | Advanced hepatocellular carcinoma (HCC) is a lethal disease, with limited therapeutic options. Mixed Lineage Kinase 3 (MLK3) is a key regulator of liver diseases, although its role in HCC remains unclear. Analysis of TCGA databases suggested elevated MAP3K11 (MLK3 gene) expression, and TMA studies showed higher MLK3 activation in human HCCs. To understand MLK3's role in HCC, we utlized carcinogen-induced HCC model and compared between wild-type and MLK3 knockout (MLK3(-/-)) mice. Our studies showed that MLK3 kinase activity is upregulated in HCC, and MLK3 deficiency alleviates HCC progression. MLK3 deficiency reduced proliferation in vivo and MLK3 inhibition reduced proliferation and colony formation in vitro. To obtain further insight into the mechanism and identify newer targets mediating MLK3-induced HCCs, RNA-sequencing analysis was performed. These showed that MLK3 deficiency modulates various gene signatures, including EMT, and reduces TGFB1&2 expressions. HCC cells overexpressing MLK3 promoted EMT via autocrine TGFbeta signaling. Moreover, MLK3 deficiency attenuated activated hepatic stellate cell (HSC) signature, which is increased in wild-type. Interestingly, MLK3 promotes HSC activation via paracrine TGFbeta signaling. These findings reveal TGFbeta playing a key role at different steps of HCC, downstream of MLK3, implying MLK3-TGFbeta axis to be an ideal drug target for advanced HCC management. |
